These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 27748845)

  • 41. Analysis of serum genome-wide microRNAs for breast cancer detection.
    Wu Q; Wang C; Lu Z; Guo L; Ge Q
    Clin Chim Acta; 2012 Jul; 413(13-14):1058-65. PubMed ID: 22387599
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy.
    Bi J; Dixit G; Zhang Y; Devor EJ; Losh HA; Newtson AM; Coleman KL; Santillan DA; Maretzky T; Thiel KW; Leslie KK
    Pharmaceuticals (Basel); 2021 Jul; 14(7):. PubMed ID: 34358108
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A computational strategy to select optimized protein targets for drug development toward the control of cancer diseases.
    Carels N; Tilli T; Tuszynski JA
    PLoS One; 2015; 10(1):e0115054. PubMed ID: 25625699
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In Vitro and In Vivo Analysis of RTK Inhibitor Efficacy and Identification of Its Novel Targets in Glioblastomas.
    Martinho O; Silva-Oliveira R; Miranda-Gonçalves V; Clara C; Almeida JR; Carvalho AL; Barata JT; Reis RM
    Transl Oncol; 2013 Apr; 6(2):187-96. PubMed ID: 23544171
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gene isoforms as expression-based biomarkers predictive of drug response in vitro.
    Safikhani Z; Smirnov P; Thu KL; Silvester J; El-Hachem N; Quevedo R; Lupien M; Mak TW; Cescon D; Haibe-Kains B
    Nat Commun; 2017 Oct; 8(1):1126. PubMed ID: 29066719
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterizing Cancer Drug Response and Biological Correlates: A Geometric Network Approach.
    Pouryahya M; Oh JH; Mathews JC; Deasy JO; Tannenbaum AR
    Sci Rep; 2018 Apr; 8(1):6402. PubMed ID: 29686393
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Spatially resolved single-molecule profiling of microRNAs in migrating cells driven by microconfinement.
    Fan Z; Li B; Wang YJ; Huang X; Li B; Wang S; Liu Y; Liu YJ; Liu B
    Chem Sci; 2022 Sep; 13(37):11197-11204. PubMed ID: 36320480
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gastrointestinal cancer: A promising horizon for cediranib?
    Villanueva MT
    Nat Rev Clin Oncol; 2012 Nov; 9(11):609. PubMed ID: 23044776
    [No Abstract]   [Full Text] [Related]  

  • 49. EV-miRNAs from breast cancer patients of plasma as potential prognostic biomarkers of disease recurrence.
    Causin RL; Polezi MR; Freitas AJA; Calfa S; Altei WF; Dias JO; Laus AC; Pessôa-Pereira D; Komoto TT; Evangelista AF; Souza CP; Reis RM; Marques MMC
    Heliyon; 2024 Jul; 10(14):e33933. PubMed ID: 39104474
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
    Evangelista AF; Oliveira RJ; O Silva VA; D C Vieira RA; Reis RM; C Marques MM
    BMC Cancer; 2021 Jan; 21(1):76. PubMed ID: 33461524
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Up-regulation of microRNA-202-3p in first trimester placenta of pregnancies destined to develop severe preeclampsia, a pilot study.
    Singh K; Williams J; Brown J; Wang ET; Lee B; Gonzalez TL; Cui J; Goodarzi MO; Pisarska MD
    Pregnancy Hypertens; 2017 Oct; 10():7-9. PubMed ID: 29153693
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MicroRNA profiling in human breast cancer cell lines exposed to the anti-neoplastic drug cediranib.
    Bordinhão AL; Evangelista AF; Oliveira RJ; Macedo T; Silveira HC; Reis RM; Marques MM
    Oncol Rep; 2016 Dec; 36(6):3197-3206. PubMed ID: 27748845
    [TBL] [Abstract][Full Text] [Related]  

  • 54. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Xu K; Yagüe E
    Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells.
    Momeny M; Sankanian G; Hamzehlou S; Yousefi H; Esmaeili F; Alishahi Z; Karimi B; Zandi Z; Shamsaiegahkani S; Sabourinejad Z; Kashani B; Nasrollahzadeh A; Mousavipak SH; Mousavi SA; Ghaffari SH
    Eur J Pharmacol; 2020 Sep; 882():173298. PubMed ID: 32593665
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 5-Fluorouracil and oxaliplatin modify the expression profiles of microRNAs in human colon cancer cells in vitro.
    Zhou J; Zhou Y; Yin B; Hao W; Zhao L; Ju W; Bai C
    Oncol Rep; 2010 Jan; 23(1):121-8. PubMed ID: 19956872
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.